Serostim®[somatropin (rdna origin) for injection] (DrugBank: Somatropin)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00082628 (ClinicalTrials.gov) | May 2004 | 13/5/2004 | Treatment of Abnormal Adipose Tissue Accumulation in HIV Patients | A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS | HIV Infections;Lipodystrophy | Drug: Serostim®[somatropin (rDNA origin) for injection] | EMD Serono | NULL | Completed | 18 Years | 60 Years | Both | 569 | Phase 3 | United States;Canada |